The Singapore Clinical Research Institute (SCRI), together with its sister programme, the Cardiovascular Disease National Collaborative Enterprise (CADENCE), is pleased to announce the signing of a Memorandum of Understanding (MOU) with Clinical Research Malaysia (CRM). This partnership aims to deepen the understanding of the healthcare and research landscape in Singapore and Malaysia, and identify potential collaborations to strengthen clinical research capabilities.

The collaboration will explore clinical trial opportunities, facilitating clinical research projects between institutions in both countries. Initiatives will be established to promote and enable knowledge exchange, innovation, and training, with the goal of improving the quality of research in Singapore, Malaysia, and the broader region.

SCRI is expanding its role as Singapore’s national coordinating body for clinical trials. By working closely with healthcare clusters, industry partners, and researchers, SCRI aims to facilitate clinical trials in Singapore and enhance the nation’s clinical research capabilities.

Similarly, CADENCE continues to drive translational cardiovascular research by engaging with industry and academic partners. This initiative creates collaborative opportunities that leverage access to the resources and research capabilities of CADENCE’s joint platforms.

Together with our partners, SCRI and CADENCE look forward to furthering collaborations that will enhance the efficiency and effectiveness of clinical trials, ultimately benefiting patients with improved therapeutic options and outcomes.